Thu, 20th Oct 2016 11:35
(ShareCast News) - Shares in AIM-listed drug manufacturer Quantum Pharma plunged nearly 50% on Tuesday morning as it said it expects the performance in the second half of the year to be "materially below market expectations" although it anticipates "strong" growth. Chief financial officer and acting
Read more(ShareCast News) - Quantum Pharma has made good progress during its first half, in line with management views, and anticipates meeting market expectations for the full year. "As previously indicated, the group's performance for the year is second-half weighted and will be dependent on the level of s
Read more(ShareCast News) - Niche pharmaceutical developer Quantum Pharma announced on Friday that its subsidiary Colonis has launched Mucodis vaginal cream. The AIM-traded company said the cream is part of the Mucodis range of in-licensed patented medical devices, which focus on treating some of the side ef
Read more(ShareCast News) - Quantum Pharma said Colonis has launched its Mucodis Rectal Gel for preventing and treating rectal mucositis, a common side effect of chemotherapy and radiotherapy in cancer patients. Mucositis is a condition characterised by pain and inflammation of the body's mucous membranes wh
Read more(ShareCast News) - Quantum Pharma chief executive Andrew Scaife has stepped down after seven years but is leaving the company with current trading running in line with management expectations. Scaife has decided to leave the Newcastle-upon-Tyne company due to family reasons but has agreed to stay un
Read more(ShareCast News) - Quantum Pharma launched the third product of its Mucodis range for the treatment of some of the side effects suffered by patients undergoing cancer treatment. Mucodis dermal spray, which reached markets on Monday, was targetted at treating radiation-induced dermatitis, a condition
Read more